Bezafibrate  suppresses endogenous cholesterol synthesis, causing the expression of an increased number of specific LDL (low density lipoproteins) receptors and thus an increased catabolism of LDL which  leads to lower plasma cholesterol.  It also suppresses the endogenous synthesis of triglycerides while simultaneously stimulating their catabolism through systemic lipoprotein lipase and hepatic lipase. Bezafibrate effectively brings about lower triglyceride levels. Bezafibrate  is commercially available under brand name Bezalip. 

Bezafibrate is used in the treatment of    Type    Ma,    lib,    III,    IV   &   V hyperlipidemias resistant to diet alone.  Dosage : Bezafibrate 200 mg is given three times daily with food.

Contraindications of Bezafibrate include: Gall bladder disease, Pregnancy, lactation, kidney or liver dysfunction, Nephrotic syndrome. Side effects of Bezafibrate are  Myalgia, diarrhoea, skin rashes, Reversible alopecia, decreased libido, G.I. upset.  Drug  Interaction:    Action  of sulphonylureas potentiated .